Biochemical markers of bone turnover - uses and limitations

Annals of Clinical Biochemistry

Volumn 51, Issue 2, 2014, Pages 189-202

  Hlaing, Thinn Thinn ^a   Compston, Juliet E ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Bone disorders; bone turnover markers; clinical studies

Indexed keywords

BONE DISORDERS; BONE TURNOVER MARKERS; CLINICAL STUDIES;

BIOLOGICAL MARKERS; BONE AND BONES; BONE RESORPTION; CLINICAL CHEMISTRY TESTS; HUMANS; OSTEOGENESIS; REFERENCE STANDARDS;

EID: 84898679418     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1177/0004563213515190     Document Type: Review

References (106)

1. Isenberg D, Maddison P, Woo P, Glass D and Breedveld F (eds) Oxford textbook of rheumatology. Oxford University Press; 2003:.
2. Burtis CA,Ashwood EA,Burns DETeitz textbook of clinical chemistry and molecular diagnostics. St Louis: Elsevier; 2006:.
3. Hill PA.Bone remodelling.Br J Orthod. 1998;25:101-107.
4. Heaney R.Remodeling and fragility.Osteoporos Int. 2003;14:S12-S15.
5. Bernardi D,Zaninotto M,Plebani M.Requirements for improving quality in the measurement of bone markers.Clin Chim Acta. 2004;346:79-86.
6. Bone biodynamics. Frost HM, ed. Boston, MA: Little Brown & Co.; 1964:315-333.
7. Textbook of osteoporosis. Khanis JA, ed. London: Blackwell science; 1996:.
8. Christenson RH.Biochemical markers of bone metabolism: an overview.Clin Biochem. 1997;30:573-593.
9. Simon LS,Krane SM,Wortman PD, et al.Serum levels of type I and III procollagen fragments in Paget's disease of bone.J Clin Endocrinol Metab. 1984;58:110-120.
10. Parfitt AM,Drezner MK,Glorieux FH, et al.Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee.J Bone Miner Res. 1987;2:595-610.
11. Samoszuk M,Leuther M,Hoyle N.Role of serum P1NP measurement for monitoring treatment response in osteoporosis.Biomark Med. 2008;2:495-508.
12. Skoumal M,Haberhauer G,Kolarz G, et al.Serum cathepsin K levels of patients with longstanding rheumatoid arthritis: correlation with radiological destruction.Arthritis Res Ther. 2005;7:R65-R70.
13. Smedsrod B,Melkko J,Risteli L, et al.Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells.Biochem J. 1990;271:345-350.
14. Parfitt AM,Simon LS,Villanueva AR, et al.Procollagen type I carboxy-terminal extension peptide in serum as a marker of collagen biosynthesis in bone. Correlation with iliac bone formation rates and comparison with total alkaline phosphatase.J Bone Miner Res. 1987;2:427-436.
15. Swaminathan R.Biochemical markers of bone turnover.Clin Chim Acta. 2001;313:95-105.
16. Garnero P,Vergnaud P,Hoyle N.Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis.Clin Chem. 2008;54:188-196.
17. Ryder KM,Tanner SB,Carbone L, et al.Teriparatide is safe and effectively increases bone biomarkers in institutionalized individuals with osteoporosis.J Bone Miner Metab. 2010;28:233-239.
18. Vescovi JD,VanHeest JL,De Souza MJ.Short-term response of bone turnover to low-dose oral contraceptives in exercising women with hypothalamic amenorrhea.Contraception. 2008;77:97-104.
19. Civitelli R,Armamento-Villareal R,Napoli N.Bone turnover markers: understanding their value in clinical trials and clinical practice.Osteoporos Int. 2009;20:843-851.
20. Delmas PD,Eastell R,Garnero P, et al.The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation.Osteoporos Int. 2000;11:S2-S17.
21. Sharp CA,Linder C,Magnusson P.Analysis of human bone alkaline phosphatase isoforms: comparison of isoelectric focusing and ion-exchange high-performance liquid chromatography.Clin Chim Acta. 2007;379:105-112.
22. Garnero P,Delmas PD.Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease.J Clin Endocrinol Metab. 1993;77:1046-1053.
23. Woitge HW,Seibel MJ,Ziegler R.Comparison of total and bone-specific alkaline phosphatase in patients with nonskeletal disorder or metabolic bone diseases.Clin Chem. 1996;42:1796-1804.
24. Takahashi M,Naitou K,Ohishi T, et al.Effect of vitamin K and/or D on undercarboxylated and intact osteocalcin in osteoporotic patients with vertebral or hip fractures.Clin Endocrinol (Oxf). 2001;54:219-224.
25. Epstein S.Serum and urinary markers of bone remodeling: assessment of bone turnover.Endocr Rev. 1988;9:438-448.
26. Power MJ,Fottrell PF.Osteocalcin: diagnostic methods and clinical applications.Crit Rev Clin Lab Sci. 1991;28:287-335.
27. Power MJ,O'Dwyer B,Breen E, et al.Osteocalcin concentrations in plasma prepared with different anticoagulants.Clin Chem. 1991;37:281-284.
28. Woitge HW,Seibel MJ.Molecular markers of bone and cartilage metabolism.Curr Opin Rheumatol. 1999;11:218-225.
29. Lee A,Hodges S,Eastell R.Measurement of osteocalcin.Ann Clin Biochem. 2000;37:432-446.
30. Nenonen A,Cheng S,Ivaska KK, et al.Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover.J Bone Miner Res. 2005;20:1804-1812.
31. Halleen JM,Alatalo SL,Suominen H, et al.Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption.J Bone Miner Res. 2000;15:1337-1345.
32. Hannon RA,Clowes JA,Eagleton AC, et al.Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption.Bone. 2004;34:187-194.
33. James IT,Walne AJ,Perrett D.The measurement of pyridinium crosslinks: a methodological overview.Ann Clin Biochem. 1996;33 (part 5): 397-420.
34. Gerrits MI,Thijssen JH,van Rijn HJ.Determination of pyridinoline and deoxypyridinoline in urine, with special attention to retaining their stability.Clin Chem. 1995;41:571-574.
35. Sinigaglia L,Varenna M,Binelli L, et al.Serum levels of pyridinium crosslinks in postmenopausal women and in Paget's disease of bone.Calcif Tissue Int. 1997;61:279-284.
36. Garnero P,Cloos P,Sornay-Rendu E, et al.Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study.J Bone Miner Res. 2002;17:826-833.
37. Garnero P,Buchs N,Zekri J, et al.Markers of bone turnover for the management of patients with bone metastases from prostate cancer.Br J Cancer. 2000;82:858-864.
38. Peris P,Alvarez L,Vidal S, et al.Biochemical response to bisphosphonate therapy in pagetic patients with skull involvement.Calcif Tissue Int. 2006;79:22-26.
39. Christgau S.Circadian variation in serum crosslaps concentration is reduced in fasting individuals.Clin Chem. 2000;46:431-431.
40. Ju HS,Leung S,Brown B, et al.Comparison of analytical performance and biological variability of three bone resorption assays.Clin Chem. 1997;43:1570-1576.
41. Garnero P,Borel O,Delmas PD.Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis.Clin Chem. 2001;47:694-702.
42. Simsek B,Karacaer O,Karaca I.Urine products of bone breakdown as markers of bone resorption and clinical usefulness of urinary hydroxyproline: an overview.Chin Med J (Engl). 2004;117:291-295.
43. Seibel MJ.Biochemical markers of bone turnover: part I: biochemistry and variability.Clin Biochem Rev. 2005;26:97-122.
44. Seibel MJ,Woitge HW,Pecherstorfer M, et al.Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease.J Clin Endocrinol Metab. 1996;81:3289-3294.
45. Stork S,Stork C,Angerer P, et al.Bone sialoprotein is a specific biochemical marker of bone metabolism in postmenopausal women: a randomized 1-year study.Osteoporos Int. 2000;11:790-796.
46. Perez-Castrillon JL,Pinacho F,De LD, et al.Odanacatib, a new drug for the treatment of osteoporosis: review of the results in postmenopausal women.J Osteoporos. 2010;2010:.
47. Holzer G,Noske H,Lang T, et al.Soluble cathepsin K: a novel marker for the prediction of nontraumatic fractures?.J Lab Clin Med. 2005;146:13-17.
48. Yasuda H,Shima N,Nakagawa N, et al.Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro.Endocrinology. 1998;139:1329-1337.
49. Rogers A,Eastell R.Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment.J Clin Endocrinol Metab. 2005;90:6323-6331.
50. Mora S,Prinster C,Proverbio MC, et al.Urinary markers of bone turnover in healthy children and adolescents: age-related changes and effect of puberty.Calcif Tissue Int. 1998;63:369-374.
51. Fatayerji D,Eastell R.Age-related changes in bone turnover in men.J Bone Miner Res. 1999;14:1203-1210.
52. Sone T,Miyake M,Takeda N, et al.Urinary excretion of type I collagen crosslinked N-telopeptides in healthy Japanese adults: age- and sex-related changes and reference limits.Bone. 1995;17:335-339.
53. Pratt JH,Manatunga AK,Peacock M.A comparison of the urinary excretion of bone resorptive products in white and black children.J Lab Clin Med. 1996;127:67-70.
54. Hannon R,Eastell R.Preanalytical variability of biochemical markers of bone turnover.Osteoporos Int. 2000;11:S30-S44.
55. Naylor KE,Iqbal P,Fledelius C, et al.The effect of pregnancy on bone density and bone turnover.J Bone Miner Res. 2000;15:129-137.
56. Ingle BM,Hay SM,Bottjer HM, et al.Changes in bone mass and bone turnover following distal forearm fracture.Osteoporos Int. 1999;10:399-407.
57. Veitch SW,Findlay SC,Hamer AJ, et al.Changes in bone mass and bone turnover following tibial shaft fracture.Osteoporos Int. 2006;17:364-372.
58. Zerwekh JE,Ruml LA,Gottschalk F, et al.The effects of twelve weeks of bed rest on bone histology, biochemical markers of bone turnover, and calcium homeostasis in eleven normal subjects.J Bone Miner Res. 1998;13:1594-1601.
59. Christensen JO,Svendsen OL.Bone mineral in pre- and postmenopausal women with insulin-dependent and non-insulin-dependent diabetes mellitus.Osteoporos Int. 1999;10:307-311.
60. Crosbie OM,Freaney R,McKenna MJ, et al.Bone density, vitamin D status, and disordered bone remodeling in end-stage chronic liver disease.Calcif Tissue Int. 1999;64:295-300.
61. Gorai I,Chaki O,Nakayama M, et al.Urinary biochemical markers for bone resorption during the menstrual cycle.Calcif Tissue Int. 1995;57:100-104.
62. Nielsen HK,Brixen K,Bouillon R, et al.Changes in biochemical markers of osteoblastic activity during the menstrual cycle.J Clin Endocrinol Metab. 1990;70:1431-1437.
63. Woitge HW,Scheidt-Nave C,Kissling C, et al.Seasonal variation of biochemical indexes of bone turnover: results of a population-based study.J Clin Endocrinol Metab. 1998;83:68-75.
64. McLaren AM,Isdale AH,Whiting PH, et al.Physiological variations in the urinary excretion of pyridinium crosslinks of collagen.Br J Rheumatol. 1993;32:307-312.
65. Takahashi M,Kawana K,Nagano A.Biological variability of biochemical markers of bone turnover in healthy women.Endocr Res. 2002;28:257-264.
66. Jensen JE,Kollerup G,Sorensen HA, et al.Intraindividual variability in bone markers in the urine.Scand J Clin Lab Invest Suppl. 1997;227:29-34.
67. Seibel MJ,Lang M,Geilenkeuser WJ.Interlaboratory variation of biochemical markers of bone turnover.Clin Chem. 2001;47:1443-1450.
68. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO study Group. Geneva: WHO, 1994.
69. Chapurlat R.[Epidemiology of osteoporosis].J Soc Biol. 2008;202:251-255.
70. FRAX WHO fracture risk assessment tool. Geneva: World Health Organization; 2008:.
71. Leslie WD,Lix LM,Johansson H, et al.Does osteoporosis therapy invalidate FRAX for fracture prediction?.J Bone Miner Res. 2012;27:1243-1251.
72. Christiansen C.Prediction of rapid bone loss in postmenopausal women.Lancet. 1987;May:1105-1108.
73. Garnero P,Sornay-Rendu E,Chapuy MC, et al.Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis.J Bone Miner Res. 1996;11:337-349.
74. Garnero P,Sornay-Rendu E,Claustrat B, et al.Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study.J Bone Miner Res. 2000;15:1526-1536.
75. Rosen CJ,Chesnut CH,Mallinak NJ.The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation.J Clin Endocrinol Metab. 1997;82:1904-1910.
76. Bauer DC,Garnero P,Harrison SL, et al.Biochemical markers of bone turnover, hip bone loss, and fracture in older men: the MrOS study.J Bone Miner Res. 2009;24:2032-2038.
77. Christiansen C,Riis BJ,Rodbro P.Prediction of rapid bone loss in postmenopausal women.Lancet. 1987;1:1105-1108.
78. Garnero P,Hausherr E,Chapuy MC, et al.Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study.J Bone Miner Res. 1996;11:1531-1538.
79. Sornay-Rendu E,Munoz F,Garnero P, et al.Identification of osteopenic women at high risk of fracture: the OFELY study.J Bone Miner Res. 2005;20:1813-1819.
80. Meier C,Nguyen TV,Center JR, et al.Bone resorption and osteoporotic fractures in elderly men: the Dubbo osteoporosis epidemiology study.J Bone Miner Res. 2005;20:579-587.
81. Riggs BL,Melton LJ.Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density.J Bone Miner Res. 2002;17:11-14.
82. Sarkar S,Mitlak BH,Wong M, et al.Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy.J Bone Miner Res. 2002;17:1-10.
83. Bauer DC,Garnero P,Hochberg MC, et al.Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial.J Bone Miner Res. 2006;21:292-299.
84. Eastell R,Barton I,Hannon RA, et al.Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.J Bone Miner Res. 2003;18:1051-1056.
85. Black DM,Delmas PD,Eastell R, et al.Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.N Engl J Med. 2007;356:1809-1822.
86. Cummings SR,San MJ,McClung MR, et al.Denosumab for prevention of fractures in postmenopausal women with osteoporosis.N Engl J Med. 2009;361:756-765.
87. Glover SJ,Eastell R,McCloskey EV, et al.Rapid and robust response of biochemical markers of bone formation to teriparatide therapy.Bone. 2009;45:1053-1058.
88. Black DM,Cummings SR,Karpf DB, et al.Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.Lancet. 1996;348:1535-1541.
89. Rizzoli R,Greenspan SL,Bone G, et al.Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis.J Bone Miner Res. 2002;17:1988-1996.
90. Clowes JA,Peel NF,Eastell R.The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial.J Clin Endocrinol Metab. 2004;89:1117-1123.
91. Delmas PD,Vrijens B,Eastell R, et al.Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis.J Clin Endocrinol Metab. 2007;92:1296-1304.
92. Paget's Association. Paget's disease-the facts, http://www.paget.org.uk/factsbooklet/factsbooklet.pdf (2010, accessed 21 November 2013).
93. Alvarez L,Guanabens N,Peris P, et al.Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease.Bone. 2001;29:447-452.
94. Gallacher SJ.Paget's disease of bone.Curr Opin Rheumatol. 1993;5:351-356.
95. Alvarez L,Ricos C,Peris P, et al.Components of biological variation of biochemical markers of bone turnover in Paget's bone disease.Bone. 2000;26:571-576.
96. Alvarez L,Peris P,Guanabens N, et al.Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.Rheumatology (Oxford). 2004;43:869-874.
97. Selby PL,Davie MW,Ralston SH, et al.Guidelines on the management of Paget's disease of bone.Bone. 2002;31:366-373.
98. Coleman RE.Clinical features of metastatic bone disease and risk of skeletal morbidity.Clin Cancer Res. 2006;12(20 part 2):6243s-6249s.
99. Brown JE,Sim S.Evolving role of bone biomarkers in castration-resistant prostate cancer.Neoplasia. 2010;12:685-696.
100. Cremers S,Garnero P.Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls.Drugs. 2006;66:2031-2058.
101. Hannon RA,Eastell R.Bone markers and current laboratory assays.Cancer Treat Rev. 2006;32:7-14.
102. Garnero P.Markers of bone turnover in prostate cancer.Cancer Treat Rev. 2001;27:187-192.
103. Leeming DJ,Koizumi M,Byrjalsen I, et al.The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients.Cancer Epidemiol Biomarkers Prev. 2006;15:32-38.
104. Seibel MJ.Clinical use of markers of bone turnover in metastatic bone disease.Nat Clin Pract Oncol. 2005;2:504-517.
105. Lipton A,Cook R,Saad F, et al.Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid.Cancer. 2008;113:193-201.
106. Vasikaran S, et al.Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards.Osteoporos Int. 2011;22:391-420.